Literature DB >> 1719240

A second neutralizing epitope of B19 parvovirus implicates the spike region in the immune response.

K Yoshimoto1, S Rosenfeld, N Frickhofen, D Kennedy, R Hills, S Kajigaya, N S Young.   

Abstract

We used 18 monoclonal antibodies against B19 parvovirus to identify neutralizing epitopes on the viral capsid. Of the 18 antibodies, 9 had in vitro neutralizing activity in a bone marrow colony culture assay. The overlapping polypeptide fragments spanning the B19 structural proteins were produced in a pMAL-c Escherichia coli expression system and used to investigate the binding sites of the neutralizing antibodies. One of the nine neutralizing antibodies reacted with both VP1 and VP2 capsid proteins and a single polypeptide fragment on an immunoblot, identifying a linear neutralizing epitope between amino acids 57 and 77 of the VP2 capsid protein. Eight of nine neutralizing antibodies failed to react with either of the capsid proteins or any polypeptide fragments, despite reactivities with intact virions in a radioimmunoassay, suggesting that additional conformationally dependent neutralizing epitopes exist.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719240      PMCID: PMC250827     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Parvovirus infections and hypoplastic crisis in sickle-cell anaemia.

Authors:  J R Pattison; S E Jones; J Hodgson; L R Davis; J M White; C E Stroud; L Murtaza
Journal:  Lancet       Date:  1981-03-21       Impact factor: 79.321

3.  Antibodies to major histocompatibility antigens produced by hybrid cell lines.

Authors:  G Galfre; S C Howe; C Milstein; G W Butcher; J C Howard
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

4.  Serologically proved intrauterine infection with parvovirus.

Authors:  P D Knott; G A Welply; M J Anderson
Journal:  Br Med J (Clin Res Ed)       Date:  1984-12-15

5.  Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions.

Authors:  S Kajigaya; H Fujii; A Field; S Anderson; S Rosenfeld; L J Anderson; T Shimada; N S Young
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

6.  Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures.

Authors:  K Ozawa; N Young
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

7.  Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV).

Authors:  B J Cohen; P P Mortimer; M S Pereira
Journal:  J Hyg (Lond)       Date:  1983-08

8.  Characterization and molecular cloning of a human parvovirus genome.

Authors:  S F Cotmore; P Tattersall
Journal:  Science       Date:  1984-12-07       Impact factor: 47.728

9.  A human parvovirus-like virus inhibits haematopoietic colony formation in vitro.

Authors:  P P Mortimer; R K Humphries; J G Moore; R H Purcell; N S Young
Journal:  Nature       Date:  1983 Mar 31-Apr 6       Impact factor: 49.962

10.  Characterization of a virus that causes transient aplastic crisis.

Authors:  N S Young; P P Mortimer; J G Moore; R K Humphries
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

View more
  15 in total

1.  Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.

Authors:  S J Rosenfeld; K Yoshimoto; S Kajigaya; S Anderson; N S Young; A Field; P Warrener; G Bansal; M S Collett
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

2.  Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.

Authors:  T Saikawa; S Anderson; M Momoeda; S Kajigaya; N S Young
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Subunit interaction in B19 parvovirus empty capsids.

Authors:  S J Rosenfeld; N S Young; D Alling; J Ayub; C Saxinger
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

Review 4.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

5.  Characterization of Parvovirus B19 genotype 2 in KU812Ep6 cells.

Authors:  Johannes Blümel; Anna Maria Eis-Hübinger; Albert Stühler; Claudia Bönsch; Matthias Gessner; Johannes Löwer
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections.

Authors:  T C Harder; M Hufnagel; K Zahn; K Beutel; H J Schmitt; U Ullmann; P Rautenberg
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

7.  Formation of empty B19 parvovirus capsids by the truncated minor capsid protein.

Authors:  S Wong; M Momoeda; A Field; S Kajigaya; N S Young
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

Review 8.  Parvovirus B19 infection.

Authors:  J R Kerr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

9.  Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins.

Authors:  A Gigler; S Dorsch; A Hemauer; C Williams; S Kim; N S Young; S Zolla-Pazner; H Wolf; M K Gorny; S Modrow
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 10.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.